

Supplementary materials

Table S1: Pcurve analysis of MAP-associated MS meta-analysis.

Study combined	pptest	pBinomial	Full Curve		Half Curve		Power Estimate	Evidential value	
			zFull	pFull	zHalf	pHalf		present	absent/inadequate
k = 12*									
TN p<0.05: k = 10 (83.33%)	Right-skewness test	0.001	-10.68	<0.001	-9.881	<0.001	99% (96.8%-99%)	yes	no
TN p<0.025: k = 10 (83.33%)	Flatness test	1	7.606	>0.999	8.641	>0.999			
k = 4**									
TN p<0.05: k = 4 (100%)	Right-skewness test	0.062	-4.934	<0.001	-4.373	<0.001	94% (72.5%-99%)	yes	no
TN p<0.025: k = 4 (100%)	Flatness test	1	3.131	>0.999	3.888	>0.999			

* Anti-MAP abs data; ** MAP DNA data; TN = total number of study;




Figure S1: Stage of multiple sclerosis disease progression. RR (relapsing remitting), SR (secondary relapsing), SP (secondary progressive), PP (primary progressive), CIS (clinically isolated syndrome) and RIS (radiologically isolated syndrome).




Figure S2. Funnel plot of pooled MAP DNA data in MAP-related MS studies. Eggers' test (intercept = -5.573, 95% CI: -20.44 - 9.29, $t = -0.74$, $p = 0.54$).